Abstract：
Tralokinumab is a human monoclonal antibody targeting interleukin-13 that is approved for the treatment of moderate-severe atopic dermatitis. Studies analyzing the efficacy and safety of tralokinumab in a real-world setting are scarce.
A European, multicentric, real-world, retrospective cohort study was defined to assess the effectiveness and safeness profile of tralokinumab, investigating the achievement of pre-specified treatment goals; and to detect potential differences in terms of effectiveness and safeness across some selected patient subcohorts.
A total of 194 adult patients were included in this study. A significant improvement in physician-assessed disease severity was detected at each follow-up visit as compared with baseline and similar trend was observed for patient-reported outcomes and quality of life. No meaningful difference in effectiveness was found when considering patient age (<65 versus ≥65 years), neither dissecting patient cohort in dupilumab-naive vs dupilumab-treated subjects. Among tralokinumab-treated patients, 88% achieved at least one currently identified real-world therapeutic goal at week 16.
This retrospective multicenter study confirmed the effectiveness and safeness of tralokinumab throughout 32 weeks of observation, showing the achievement of therapeutic goals identified in both trial and real-world settings in a large proportion of tralokinumab-treated patients.
A European, multicentric, real-world, retrospective cohort study was defined to assess the effectiveness and safeness profile of tralokinumab, investigating the achievement of pre-specified treatment goals; and to detect potential differences in terms of effectiveness and safeness across some selected patient subcohorts.
A total of 194 adult patients were included in this study. A significant improvement in physician-assessed disease severity was detected at each follow-up visit as compared with baseline and similar trend was observed for patient-reported outcomes and quality of life. No meaningful difference in effectiveness was found when considering patient age (<65 versus ≥65 years), neither dissecting patient cohort in dupilumab-naive vs dupilumab-treated subjects. Among tralokinumab-treated patients, 88% achieved at least one currently identified real-world therapeutic goal at week 16.
This retrospective multicenter study confirmed the effectiveness and safeness of tralokinumab throughout 32 weeks of observation, showing the achievement of therapeutic goals identified in both trial and real-world settings in a large proportion of tralokinumab-treated patients.
摘要：
■曲洛金单抗是一种靶向白细胞介素-13的人单克隆抗体，已被批准用于治疗中重度特应性皮炎。在现实世界中分析曲洛金单抗的疗效和安全性的研究很少。
■欧洲，多中心,真实世界,回顾性队列研究旨在评估曲洛金单抗的有效性和安全性，调查预先指定的治疗目标的实现;并检测一些选定的患者亚组在有效性和安全性方面的潜在差异。
■本研究共纳入194名成年患者。与基线相比，每次随访时，医生评估的疾病严重程度均有显着改善，并且患者报告的结局和生活质量观察到相似的趋势。考虑患者年龄（<65岁与≥65岁）时，有效性没有发现有意义的差异，在dupilumab初治和dupilumab治疗的受试者中均未进行解剖患者队列.在曲洛金单抗治疗的患者中，88%的人在第16周实现了至少一个目前确定的现实世界治疗目标。
■这项回顾性多中心研究证实了曲洛金单抗在32周观察期间的有效性和安全性，显示大部分曲洛金单抗治疗患者在试验和现实环境中确定的治疗目标的实现.
■欧洲，多中心,真实世界,回顾性队列研究旨在评估曲洛金单抗的有效性和安全性，调查预先指定的治疗目标的实现;并检测一些选定的患者亚组在有效性和安全性方面的潜在差异。
■本研究共纳入194名成年患者。与基线相比，每次随访时，医生评估的疾病严重程度均有显着改善，并且患者报告的结局和生活质量观察到相似的趋势。考虑患者年龄（<65岁与≥65岁）时，有效性没有发现有意义的差异，在dupilumab初治和dupilumab治疗的受试者中均未进行解剖患者队列.在曲洛金单抗治疗的患者中，88%的人在第16周实现了至少一个目前确定的现实世界治疗目标。
■这项回顾性多中心研究证实了曲洛金单抗在32周观察期间的有效性和安全性，显示大部分曲洛金单抗治疗患者在试验和现实环境中确定的治疗目标的实现.
